Treatment Resistant Depression in America Latina

NCT ID: NCT03207282

Last Updated: 2025-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1539 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-27

Study Completion Date

2019-11-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries: Argentina, Brazil, Colombia and Mexico; and to evaluate all and depression-related healthcare resource utilization in TRD participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Treatment-Resistant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Diagnosis of Depression

Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Phase 1:

* Major depressive disorder (MDD) diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), that was confirmed by MINI International Neuropsychiatric Interview, 5.0 version (MINI)
* Treated or untreated participants with a new or continued episode of depression at the time of the enrolment
* Participants must be capable of completing the corresponding assessments in the study
* Participants must be capable of signing the informed consent form

Phase 2:

* Diagnosis of Treatment Resistant Depression (TRD), to be described by the investigator, based on the criteria:

1. Adequate follow-up and treatment with at least 2 antidepressants
2. Without complete response to treatment (based on Montgomery-Asberg Depression Rating Scale \[MADRS\])

Exclusion Criteria

* Participants diagnosed of psychosis, schizophrenia, bipolar disorder, schizoaffective disorder, or dementia
* Participants with substance dependence considered serious by the investigator
* Participant currently participating in another clinical study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen-Cilag, S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jannsen Cilag S.A. Clinical Trial

Role: STUDY_DIRECTOR

Jannsen Cilag S.A.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales

Buenos Aires, , Argentina

Site Status

Instituto DAMIC

Córdoba, , Argentina

Site Status

Clinica Privada de Salud Mental Santa Teresa de Ávila

La Plata, , Argentina

Site Status

CESASIN

Mendoza, , Argentina

Site Status

C I A P Centro de investigacion y Asistencia en Psiquiatria

Rosario, , Argentina

Site Status

Universidade Federal De Minas Gerais - Hospital das Clínicas

Belo Horizonte, , Brazil

Site Status

Instituto De Neurociencias Dr. Quevedo Hospital Sao Sebastiao

Criciúma, , Brazil

Site Status

Trial Tech Tecnologia em Pesquisas com Medicamentos

Curitiba, , Brazil

Site Status

Universidade Federal Do Ceara

Fortaleza, , Brazil

Site Status

Instituto Bairral de Psiquiatria

Itapira, , Brazil

Site Status

Faculdade de Medicina da Universidade Federal de Pelotas

Pelotas, , Brazil

Site Status

Hospital das Clinicas de Porto Alegre

Porto Alegre, , Brazil

Site Status

Universidade Federal do Rio de Janeiro - Instituto de Psiquiatria

Rio de Janeiro, , Brazil

Site Status

Hospital Universitario Professor Edgar Santos

Salvador, , Brazil

Site Status

Hospital Das Clinicas Da Faculdade De Medicina Da USP

São Paulo, , Brazil

Site Status

HOMO - ESE Hospital Mental de Antioquia

Bello, , Colombia

Site Status

Instituto Colombiano del Sistema Nervioso

Bogotá, , Colombia

Site Status

Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.

Bogotá, , Colombia

Site Status

Conciencia S.A.S

Medellín - Antioquia, , Colombia

Site Status

Hospital Psiquiátrico Granja la Salud Tlazolteotl

Ixtapaluca, , Mexico

Site Status

Hospital Aranda de la Parra S A de C V

León, , Mexico

Site Status

Grupo de Estudios Médicos y familiares Carraci SC

Mexico City, , Mexico

Site Status

Estimulación Magnética Transcraneal de México S.C.

Mexico City, , Mexico

Site Status

Hospital Psiquiatrico Fray Bernardino Alvarez

Mexico City, , Mexico

Site Status

Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz

Mexico City, , Mexico

Site Status

Clínica de Neuropsiquiatría Tlatelolco ISSSTE

Mexico City, , Mexico

Site Status

Instituto Nacional de Neurología y Neurocirugía

México, , Mexico

Site Status

Privarte Practice of Dr. Javier Zambrano

México, , Mexico

Site Status

Instituto Jalisciense de Salud Mental

México, , Mexico

Site Status

Centro para las Adicciones y Salud Mental S.A. de C.V.

Monterrey, , Mexico

Site Status

cit NEUROPSIQUE

Monterrey, , Mexico

Site Status

Hospital Central Dr Ignacio Morones Prieto

San Luis Potosí City, , Mexico

Site Status

Clínica de Consulta Externa Alfredo del Mazo Vélez ISSEMyM

Toluca, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Brazil Colombia Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Soares B, Kanevsky G, Teng CT, Perez-Esparza R, Bonetto GG, Lacerda ALT, Uribe ES, Cordoba R, Lupo C, Samora AM, Cabrera P. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study. Psychiatr Q. 2021 Dec;92(4):1797-1815. doi: 10.1007/s11126-021-09930-x. Epub 2021 Aug 31.

Reference Type DERIVED
PMID: 34463905 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

54135419RSD4001

Identifier Type: OTHER

Identifier Source: secondary_id

CR108329

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Major Depressive Disorder (MDD)
NCT01662817 COMPLETED
The Antidepressant Advisor Study
NCT03628027 UNKNOWN PHASE2